التفاصيل البيبلوغرافية
| العنوان: |
2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. |
| المؤلفون: |
Mingwei Wei, Fanyue Meng, Shiyuan Wang, Jingxin Li, Yuntao Zhang, Qunying Mao, Yuemei Hu, Pei Liu, Nianmin Shi, Hong Tao, Kai Chu, Yuxiao Wang, Zhenglun Liang, Xiuling Li, Fengcai Zhu, Wei, Mingwei, Meng, Fanyue, Wang, Shiyuan, Li, Jingxin, Zhang, Yuntao |
| المصدر: |
Journal of Infectious Diseases; Jan2017, Vol. 215 Issue 1, p56-63, 8p |
| مصطلحات موضوعية: |
IMMUNOGENETICS, VACCINE biotechnology, PLACEBOS, INFANT care, IMMUNOLOGY, ANIMAL experimentation, CLINICAL trials, COMPARATIVE studies, ENTEROVIRUS diseases, ENTEROVIRUSES, IMMUNIZATION, IMMUNOGLOBULINS, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, MEDICAL protocols, RESEARCH, TIME, VACCINES, VIRAL antibodies, VIRAL vaccines, EVALUATION research, RANDOMIZED controlled trials, BLIND experiment, PREVENTION |
| مصطلحات جغرافية: |
CHINA |
| مستخلص: |
Background: This study evaluated the 2-year efficacy, immunogenicity, and safety of the Vigoo enterovirus 71 (EV71) vaccine.Method: In an initial phase 3 study, we randomly assigned healthy infants and children aged 6-35 months (ratio, 1:1) to receive 2 doses of either EV71 vaccine (5120 participants) or placebo (5125 participants) at days 0 and 28, and followed them for 12 months after vaccination. In this extended follow-up study, we continued to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine for up to 2 years.Results: Overall efficacy was 94.84% (95% confidence interval [CI], 83.53%-98.38%) during the 2-year follow-up period (P < .0001), and the vaccine efficacy during the second year was 100.00% (95% CI, 84.15%-100.00%) against EV71-associated hand-foot-and-mouth disease (HFMD; P < .0001). Geometric mean titers of neutralizing antibody in participants remained high during the 2-year follow-up period, and no vaccine-related serious adverse events were recorded.Conclusions: Two doses of Vigoo EV71 vaccine could provide sustained protection against EV71-associated HFMD in healthy Chinese children.Clinical Trials Registration: NCT01508247. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
